XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.25.1

Product and Geographic Information (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Segment Reporting [Abstract] |
Schedule of Sales of Company's Products | Revenues of the Company’s products were as follows:
|  |  | Three Months Ended March 31,
|  |  |  |  | 2025 |  | 2024 |  |
($ in millions) |  |  |  |  |  |  |  |  |  |  |  |  | U.S. |  | Int’l |  | Total |  | U.S. |  | Int’l |  | Total |  |  |  |  |  |
Women’s Health |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nexplanon/Implanon NXT |  |  |  |  |  |  |  |  |  |  |  |  | $ | 176 |  |  | $ | 72 |  |  | $ | 248 |  |  | $ | 153 |  |  | $ | 67 |  |  | $ | 220 |  |  |  |  |  |  |
Follistim AQ |  |  |  |  |  |  |  |  |  |  |  |  | 35 |  |  | 34 |  |  | 69 |  |  | 11 |  |  | 35 |  |  | 46 |  |  |  |  |  |  |
NuvaRing |  |  |  |  |  |  |  |  |  |  |  |  | 6 |  |  | 16 |  |  | 22 |  |  | 16 |  |  | 22 |  |  | 38 |  |  |  |  |  |  |
Ganirelix Acetate Injection |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  | 23 |  |  | 27 |  |  | 6 |  |  | 23 |  |  | 29 |  |  |  |  |  |  |
Marvelon/Mercilon |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 39 |  |  | 39 |  |  | — |  |  | 33 |  |  | 33 |  |  |  |  |  |  |
Jada |  |  |  |  |  |  |  |  |  |  |  |  | 15 |  |  | — |  |  | 15 |  |  | 13 |  |  | — |  |  | 13 |  |  |  |  |  |  |
Other Women’s Health (1) |  |  |  |  |  |  |  |  |  |  |  |  | 15 |  |  | 27 |  |  | 43 |  |  | 15 |  |  | 28 |  |  | 43 |  |  |  |  |  |  |
Biosimilars |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Renflexis |  |  |  |  |  |  |  |  |  |  |  |  | 44 |  |  | 12 |  |  | 57 |  |  | 55 |  |  | 14 |  |  | 69 |  |  |  |  |  |  |
Hadlima |  |  |  |  |  |  |  |  |  |  |  |  | 33 |  |  | 14 |  |  | 47 |  |  | 22 |  |  | 8 |  |  | 30 |  |  |  |  |  |  |
Ontruzant |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  | 14 |  |  | 18 |  |  | 8 |  |  | 31 |  |  | 39 |  |  |  |  |  |  |
Brenzys |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 14 |  |  | 14 |  |  | — |  |  | 24 |  |  | 24 |  |  |  |  |  |  |
Aybintio |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 5 |  |  | 5 |  |  | — |  |  | 8 |  |  | 8 |  |  |  |  |  |  |
Established Brands |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atozet |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 77 |  |  | 77 |  |  | — |  |  | 132 |  |  | 132 |  |  |  |  |  |  |
Zetia |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  | 84 |  |  | 85 |  |  | 2 |  |  | 82 |  |  | 84 |  |  |  |  |  |  |
Cozaar/Hyzaar |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  | 53 |  |  | 55 |  |  | 3 |  |  | 65 |  |  | 67 |  |  |  |  |  |  |
Vytorin |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  | 22 |  |  | 23 |  |  | 1 |  |  | 27 |  |  | 28 |  |  |  |  |  |  |
Rosuzet |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 4 |  |  | 4 |  |  | — |  |  | 16 |  |  | 16 |  |  |  |  |  |  |
Other Cardiovascular (1) |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 30 |  |  | 30 |  |  | — |  |  | 37 |  |  | 38 |  |  |  |  |  |  |
Respiratory |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Singulair |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  | 72 |  |  | 74 |  |  | 2 |  |  | 95 |  |  | 98 |  |  |  |  |  |  |
Nasonex |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 71 |  |  | 72 |  |  | — |  |  | 77 |  |  | 77 |  |  |  |  |  |  |
Dulera |  |  |  |  |  |  |  |  |  |  |  |  | 34 |  |  | 10 |  |  | 43 |  |  | 43 |  |  | 13 |  |  | 56 |  |  |  |  |  |  |
Clarinex |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 34 |  |  | 34 |  |  | 1 |  |  | 36 |  |  | 37 |  |  |  |  |  |  |
Other Respiratory (1) |  |  |  |  |  |  |  |  |  |  |  |  | 10 |  |  | 3 |  |  | 13 |  |  | 7 |  |  | 3 |  |  | 9 |  |  |  |  |  |  |
Non-Opioid Pain, Bone and Dermatology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Arcoxia |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 62 |  |  | 62 |  |  | — |  |  | 75 |  |  | 75 |  |  |  |  |  |  |
Fosamax |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  | 32 |  |  | 33 |  |  | 1 |  |  | 38 |  |  | 40 |  |  |  |  |  |  |
Diprospan |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 30 |  |  | 30 |  |  | — |  |  | 29 |  |  | 29 |  |  |  |  |  |  |
Vtama |  |  |  |  |  |  |  |  |  |  |  |  | 20 |  |  | 4 |  |  | 24 |  |  | — |  |  | — |  |  | — |  |  |  |  |  |  |
Other Non-Opioid Pain, Bone and Dermatology (1) |  |  |  |  |  |  |  |  |  |  |  |  | 4 |  |  | 65 |  |  | 68 |  |  | 5 |  |  | 68 |  |  | 72 |  |  |  |  |  |  |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Propecia |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  | 24 |  |  | 26 |  |  | 2 |  |  | 21 |  |  | 23 |  |  |  |  |  |  |
Emgality/Rayvow |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 32 |  |  | 32 |  |  | — |  |  | 10 |  |  | 10 |  |  |  |  |  |  |
Proscar |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 24 |  |  | 24 |  |  | — |  |  | 26 |  |  | 26 |  |  |  |  |  |  |
Other (1) |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  | 76 |  |  | 78 |  |  | 5 |  |  | 79 |  |  | 84 |  |  |  |  |  |  |
Other (2) |  |  |  |  |  |  |  |  |  |  |  |  | — |  |  | 22 |  |  | 22 |  |  | — |  |  | 29 |  |  | 29 |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  | $ | 412 |  |  | $ | 1,101 |  |  | $ | 1,513 |  |  | $ | 371 |  |  | $ | 1,251 |  |  | $ | 1,622 |  |  |  |  |  |  |
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies. (1) Includes sales of products not listed separately. (2) Includes manufacturing sales to third parties.
Schedule of Consolidated Revenues by Geographic Area | Revenues by geographic area where derived are as follows:
|  |  | Three Months Ended March 31,
($ in millions) |  |  |  |  | 2025 |  | 2024 |  |
Europe and Canada |  |  |  |  | $ | 376 |  |  | $ | 450 |  |  |
United States |  |  |  |  | 412 |  |  | 371 |  |  |
Asia Pacific and Japan |  |  |  |  | 251 |  |  | 287 |  |  |
China |  |  |  |  | 204 |  |  | 206 |  |  |
Latin America, Middle East, Russia, and Africa |  |  |  |  | 240 |  |  | 274 |  |  |
Other (1) |  |  |  |  | 30 |  |  | 34 |  |  |
Revenues |  |  |  |  | $ | 1,513 |  |  | $ | 1,622 |  |  |
(1) Includes manufacturing sales to third parties.

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration